GNPXGenprex, Inc.Signing up patients
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Small Cell Lung Cancer Extensive Stage
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 62 (planned)
- Started
- May 9, 2024
- Main results expected
- Dec 2027
- Fully finished
- Jun 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) - Phase 1
Measured over: First 21-days at each dose level
Progression-Free Survival Rate (PFSR) - Phase 2
Measured over: 18-weeks from Day 1 of maintenance therapy
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05703971 · record last updated 2026-09-11 · checked 2026-11-09 15:47 UTC